ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
67.807,25
0,12%
Brent Oil
80,74
-0,68%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) Notícias

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SXTP
DataHoraFonteTítuloCódigoCompanhia
30/05/202408:59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/05/202408:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/05/202414:45GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/05/202408:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/05/202408:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/04/202408:58GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/03/202408:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/02/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/02/202409:59GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/02/202409:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/02/202417:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202414:00PR Newswire (US)WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/01/202413:15GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202411:45PR Newswire (US)WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202411:00GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/01/202409:59GlobeNewswire Inc.60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
16/01/202409:59GlobeNewswire Inc.60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
26/12/202309:59GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/11/202309:29GlobeNewswire Inc.60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/10/202309:31GlobeNewswire Inc.60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/10/202317:16GlobeNewswire Inc.60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
18/09/202317:16GlobeNewswire Inc.60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202308:31GlobeNewswire Inc.60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/08/202308:32GlobeNewswire Inc.60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/08/202308:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/08/202308:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
31/07/202308:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/07/202314:30PR Newswire (US)WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per UnitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/07/202313:39GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Closing of Initial Public OfferingNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SXTP

Seu Histórico Recente

BIT
UC63G5
Unicredit Bank
NYSE
O-F
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados